Core Viewpoint - The article emphasizes the importance of value investing and highlights Sanofi (SNY) as a strong candidate for value investors due to its favorable financial metrics and Zacks Rank. Company Analysis - Sanofi (SNY) has a Zacks Rank of 2 (Buy) and an A grade for Value, indicating strong potential for value investors [4] - The current P/E ratio for SNY is 12.34, significantly lower than the industry average of 19.50, suggesting that SNY may be undervalued [4] - SNY's Forward P/E has fluctuated between 9.45 and 12.68 over the past year, with a median of 11.30 [4] - The PEG ratio for SNY is 1.48, which is slightly below the industry average of 1.51, indicating reasonable growth expectations relative to its valuation [5] - SNY's PEG ratio has ranged from 1.20 to 2.43 in the last 12 months, with a median of 1.51 [5] - The P/S ratio for SNY is 3.01, compared to the industry average of 4.77, further supporting the notion of undervaluation [6] - SNY's P/CF ratio is 15.48, which is attractive compared to the industry's average of 29.61, indicating strong cash flow relative to its valuation [7] - The P/CF ratio for SNY has varied between 8.04 and 15.73 over the past year, with a median of 11.50 [7] - Overall, the financial metrics suggest that Sanofi is likely undervalued and stands out as one of the strongest value stocks in the market [8] Industry Context - Value investing remains a popular strategy across various market environments, focusing on identifying undervalued companies through fundamental analysis [2] - The Style Scores system can help investors identify stocks with specific traits, particularly in the "Value" category, where stocks with high Zacks Ranks and "A" grades for Value are considered top picks [3]

Regeneron Pharmaceuticals, Inc. (REGN) announced that the blockbuster asthma drug Dupixent (dupilumab) has been recommended by the European Medicines Agency's Committee for Medicinal Products for Human Use ("CHMP") for approval for an additional indication. The CHMP recommended the label expansion of Dupixent in the European Union (EU) for eosinophilic esophagitis (EoE) in children down to 1 year of age. The recommendation is for children aged 1 to 11 years who weigh at least 15 kg and are inadequately cont ...

Sanofi (SNY) announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination with Velcade (bortezomib), Bristol Myers' (BMY) Revlimid (lenalidomide) and dexamethasone (VRd) for the treatment of patients with newly diagnosed MM (NDMM) who are not eligible forautologous stem cell transplant (ASCT). The FDA's approval is based on data from the phase III IMROZ study, which evaluated Sarclisa plus ...

Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free survival (PFS), compared to standard-of-care in newly diagnosed adult patients not eligible for autologous stem cell transpl ...

Sanofi (NASDAQ:SNY) ECTRIMS 2024 Investor Science Call September 20, 2024 10:00 AM ET Company Participants Thomas Kudsk - IR Jiwon Oh - MD, PhD, St. Michael's Hospital, University of Toronto, Toronto, Canada Robert Fox - MD, Mellen Center for MS, Cleveland Clinic, Cleveland, USA Houman Ashrafian - EVP, Head of Research and Development Erik Wallstroem - Global Senior VP, Head, Neurology Development Conference Call Participants Peter Verdult - Citi Colin Wyatt - Jefferies Luisa Hector - Berenberg Emily Field ...

Company and Industry Key Points **1. Tolebrutinib Phase 3 Data**: * **GEMINI 1 and 2 Trials**: Phase 3 trials evaluating Tolebrutinib in relapsing MS compared to Teriflunomide. No significant difference in annualized relapse rate, but a 29% risk reduction in confirmed disability worsening at six months with Tolebrutinib vs. Teriflunomide [7-13]. * **HERCULES Trial**: Phase 3 trial evaluating Tolebrutinib in non-relapsing secondary progressive MS. 31% risk reduction in time to six-month confirmed disability progression and 88% increase in six-month confirmed disability improvement vs. placebo [21-25]. * **Liver Safety**: 5.6% of Tolebrutinib-treated patients experienced liver enzyme elevation >3x upper limit of normal. All cases resolved without sequelae and occurred within the first 90 days of treatment [17-19, 27-28]. **2. Tolebrutinib's Mechanism of Action**: * Tolebrutinib appears to have a clear effect on reducing disability accumulation, independent of relapse rate or focal inflammatory disease. This suggests a potential for a new standard of care in SPMS [18, 20, 30]. **3. Frexalimab**: * Frexalimab, a CD40-Ligand inhibitor, is being investigated for MS. Phase 2 data shows promising results with low ARR and stable EDSS [36-37]. **4. Sanofi's Commitment to MS**: * Sanofi has a strong commitment to MS and is developing a comprehensive portfolio of treatments, including Tolebrutinib, Frexalimab, and other molecules [33-37]. Additional Important Points **1. Regulatory Approval**: * Sanofi plans to submit regulatory filings for Tolebrutinib in SPMS and is working on FDA labeling strategies [76-77]. **2. Patient Access**: * Sanofi aims to accelerate approval and make Tolebrutinib available to patients as soon as possible [32, 33]. **3. Future Research**: * Sanofi plans to conduct further research on Tolebrutinib and Frexalimab, including subgroup analyses and studies in other MS populations [95-97].

Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study Data presented at ECTRIMS show that tolebrutinib, a brain-penetrant BTK inhibitor, addresses disability accumulation that occurs independently from relapse activity Global regulatory submissions will begin in H2 2024 Paris, September 20, 2024. Positive results from the HERCULES phase 3 study in people with non-relapsing secondary progressive multi ...

Sanofi's (SNY) stock has gained 22.7% in the past three months compared with an increase of 2.9% for the industry. The stock has also outperformed the sector and the S&P 500 index as seen in the chart below. SNY Stock Outperforms Industry, Sector & S&P 500 Image Source: Zacks Investment Research The stock has also been consistently trading above its 50-day and 200-day moving averages since the end of June. One of the main reasons for the stock price increase in the past three months was Sanofi's increase in ...

Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has approved blockbuster drug Dupixent (dupilumab) for the indication of chronic rhinosinusitis with nasal polyps (CRSwNP) for a broader population. The regulatory body approved the drug as an add-on maintenance treatment for adolescent patients aged 12 to 17 years with inadequately controlled CRSwNP. The latest approval expands the initial FDA approval (granted in June 2019) in CRSwNP for patients aged 18 years and older. Regeneron's shares have ...

Company planning for every eligible baby in the US to have access to BEYFORTUS New BEYFORTUS filling line approved by the U.S. Food and Drug Administration (FDA) to expand manufacturing capacity and help meet demand 2 out of 3 babies get respiratory syncytial virus (RSV) disease1 BRIDGEWATER, N.J., Sept. 16, 2024 /PRNewswire/ -- Sanofi is shipping BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection doses in the US to private healthcare providers and to the Centers for Disease Control and Prevention for its ...